DDR on DTC: QuillivantXR

Share this article:
Deborah Dick-Rath
Deborah Dick-Rath

Sometimes the regulatory environment can be more than challenging for a brand, it can be debilitating. I was recently reading People magazine and noticed a detail aid in there masquerading as a DTC ad for Pfizer's QuillivantXR. How times have changed. Pfizer, once a mighty powerhouse of DTC innovation blasting groundbreaking campaigns for Viagra, Lipitor, Zyrtec and Zoloft, has been relegated (or should I say regulated?)  to running this “ad-like object” for its new ADHD brand.

 

Unfortunately, Quillivant is in a scheduled category loaded with warnings and PR issues, so we have to admire Pfizer and the Quillivant team for putting their brand out there at all—and not just in a below-radar, in-office publication, but in one of the biggest magazines guaranteed to reach their target audience of moms. That's the good news. The bad news is that the creative was limited to a wall of ISI with a bullet list of product features. There is no emotional insight or context to resonate with the target.

A box in the lower right corner contains a tiny call-to-action and the URL. The website mirrors the print ad imagery and you can register for the typical CRM and co-pay opportunities. Like a detail aid, we have a logo shot on the ad—in this case, a liquid “Q” to show that the product comes in liquid form. But unlike a detail aid, we don't get a human being to tell us the story of the brand—and sadly, this ad alone doesn't either.


Deborah Dick-Rath is the president of Epic Proportions, a healthcare communications consultancy. She can be reached at deborahdrath@optonline.net
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...